Although acute lymphoblastic leukemia is curable in one third of adult patients, results vary
greatly on account of different clinical, immunologic, and cytogenetic/genetic characteristics …

Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a
standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute …

Abstract Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in
hematologic complete remission after multiagent therapy exhibit minimal residual disease …

Importance Minimal residual disease (MRD) refers to the presence of disease in cases
deemed to be in complete remission by conventional pathologic analysis. Assessing the …

The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic
lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related …

Quantification of minimal residual disease (MRD) by real-time PCR directed to TCR and Ig
gene rearrangements allows a refined evaluation of response in acute lymphoblastic …

With intensified pediatric-like therapy and genetic disease dissection, the field of adult acute
lymphoblastic leukemia (ALL) has evolved recently. In this new context, we aimed to …

Because a pediatric-inspired Group for Research on Adult Acute Lymphoblastic Leukemia
(GRAALL) protocol yielded a markedly improved outcome in adults with Philadelphia …

Purpose Minimal residual disease (MRD) is an important prognostic factor in adults with
acute lymphoblastic leukemia (ALL) and may be used for treatment decisions. The …

To identify new markers for minimal residual disease (MRD) detection in acute
lymphoblastic leukemia (ALL), we compared genome-wide gene expression of …